PDGFRA and gastrointestinal stromal tumor: Recent developments in the management of advanced GIST include the approval of ripretinib for fourth-line treatment [9] and avapritinib for GIST harboring a PDGFRA exon 18 mutation, such as the PDGFRA D842V mutation [10], which confers primary resistance to imatinib and is found in approximately 8% of tumors [5].